DE112020003843T5 - Verbesserte Lipid-Nanopartikel zur Zuführung von Nukleinsäuren - Google Patents

Verbesserte Lipid-Nanopartikel zur Zuführung von Nukleinsäuren Download PDF

Info

Publication number
DE112020003843T5
DE112020003843T5 DE112020003843.2T DE112020003843T DE112020003843T5 DE 112020003843 T5 DE112020003843 T5 DE 112020003843T5 DE 112020003843 T DE112020003843 T DE 112020003843T DE 112020003843 T5 DE112020003843 T5 DE 112020003843T5
Authority
DE
Germany
Prior art keywords
alkyl
independently
lipid
occurrence
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE112020003843.2T
Other languages
German (de)
English (en)
Inventor
K. Tam Ying
Paulo Jia Ching Lin
Sean Semple
Christopher J. Barbosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acuitas Therapeutics Inc
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72322523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE112020003843(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Publication of DE112020003843T5 publication Critical patent/DE112020003843T5/de
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE112020003843.2T 2019-08-14 2020-08-14 Verbesserte Lipid-Nanopartikel zur Zuführung von Nukleinsäuren Pending DE112020003843T5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886894P 2019-08-14 2019-08-14
US62/886,894 2019-08-14
PCT/US2020/046407 WO2021030701A1 (en) 2019-08-14 2020-08-14 Improved lipid nanoparticles for delivery of nucleic acids

Publications (1)

Publication Number Publication Date
DE112020003843T5 true DE112020003843T5 (de) 2022-05-19

Family

ID=72322523

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112020003843.2T Pending DE112020003843T5 (de) 2019-08-14 2020-08-14 Verbesserte Lipid-Nanopartikel zur Zuführung von Nukleinsäuren

Country Status (32)

Country Link
US (1) US20230097090A1 (https=)
EP (2) EP4454640A3 (https=)
JP (2) JP7753190B2 (https=)
KR (1) KR20220053599A (https=)
CN (1) CN114901253A (https=)
AU (1) AU2020328596B2 (https=)
BR (1) BR112022002708A2 (https=)
CA (1) CA3150458A1 (https=)
CL (1) CL2022000351A1 (https=)
CO (1) CO2022002685A2 (https=)
CR (1) CR20220108A (https=)
DE (1) DE112020003843T5 (https=)
DK (1) DK4013385T3 (https=)
DO (1) DOP2022000038A (https=)
EC (1) ECSP22018209A (https=)
ES (2) ES2992930T3 (https=)
FI (1) FI4013385T3 (https=)
GB (1) GB2600859B (https=)
GE (2) GEAP202515904A (https=)
HR (1) HRP20241255T1 (https=)
HU (1) HUE068356T2 (https=)
IL (1) IL290477A (https=)
JO (1) JOP20220037A1 (https=)
LT (1) LT4013385T (https=)
MX (2) MX2022001720A (https=)
PE (1) PE20220968A1 (https=)
PH (1) PH12022550363A1 (https=)
PL (1) PL4013385T3 (https=)
PT (1) PT4013385T (https=)
SI (1) SI4013385T1 (https=)
UA (1) UA129330C2 (https=)
WO (1) WO2021030701A1 (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
WO2020097493A1 (en) 2018-11-09 2020-05-14 Arbutus Biopharma Corporation Negatively charged peg-lipid conjugates
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN113402404B (zh) * 2021-04-30 2022-03-11 苏州科锐迈德生物医药科技有限公司 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
KR20240008872A (ko) * 2021-05-06 2024-01-19 아크투루스 쎄라퓨틱스, 인크. Rna 전달을 위한 이온화 가능한 양이온성 지질
CN115385820B (zh) * 2021-05-09 2025-04-29 英维沃生物科技(苏州)有限公司 阳离子脂质及其应用
US12508225B2 (en) 2021-05-28 2025-12-30 Beijing Tricisionbio Therapeutics Inc. Lipid compound and use thereof in delivery of nucleic acid
CN113403313B (zh) * 2021-06-23 2022-08-19 北京理工大学 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用
EP4342929B1 (en) * 2021-06-30 2026-02-04 Jenkem Technology Co. Ltd. (Tianjin) Polyethylene glycol lipid and use thereof
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN115403761B (zh) * 2021-07-23 2025-04-25 天津键凯科技有限公司 一种多元甘醇修饰的脂质化合物及其制备方法和应用
CN115710191B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
CN115869262A (zh) * 2021-09-27 2023-03-31 广州谷森制药有限公司 新型peg脂质化合物、其制备方法、组合物及应用
AR127312A1 (es) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
WO2023061460A1 (zh) * 2021-10-15 2023-04-20 厦门赛诺邦格生物科技股份有限公司 含氮的阳离子脂质及其应用
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
JP2024544953A (ja) * 2021-11-11 2024-12-05 オハイオ ステート イノベーション ファウンデーション アミノ脂質化合物を含む組成物ならびにその製造方法及び使用方法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114957027B (zh) * 2022-01-13 2023-05-19 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
TW202330457A (zh) * 2022-01-19 2023-08-01 大陸商蘇州艾博生物科技有限公司 脂質化合物和脂質奈米顆粒組合物
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN116969851A (zh) * 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN117263818A (zh) * 2022-06-14 2023-12-22 杭州高田生物医药有限公司 阳离子脂质化合物及其制备方法和应用
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN117417264B (zh) * 2022-07-19 2025-12-16 深圳深信生物科技有限公司 氨基脂质化合物、其制备方法和应用
WO2024022263A1 (zh) * 2022-07-25 2024-02-01 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
EP4565572A1 (en) * 2022-08-05 2025-06-11 Life Technologies Corporation Lipids for nucleic acid delivery
JP2025530171A (ja) * 2022-09-07 2025-09-11 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤で使用するための脂質
CN120554239A (zh) * 2022-09-09 2025-08-29 厦门赛诺邦格生物科技股份有限公司 一种碳核阳离子脂质
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN115417779B (zh) * 2022-11-03 2023-06-16 北京华芢生物技术有限公司 可离子化的阳离子脂c6-a1及由其组成的纳米脂质体颗粒
CN115417780B (zh) * 2022-11-04 2023-06-20 北京华芢生物技术有限公司 可离子化的阳离子脂c5-a2及由其组成的纳米脂质体颗粒
WO2024119098A1 (en) * 2022-12-02 2024-06-06 Prime Medicine, Inc. Lipid nanoparticle (lnp) delivery systems and formulations
WO2024131810A1 (en) * 2022-12-21 2024-06-27 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
CN117384055B (zh) * 2023-04-27 2024-11-19 仁景(苏州)生物科技有限公司 用于递送治疗剂的可电离脂质及其用途
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN116891423B (zh) * 2023-07-07 2024-03-01 荣灿生物医药技术(上海)有限公司 脂质化合物、组合物及其制备方法和应用
CN119791061A (zh) * 2023-10-11 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种甲型肝炎病毒感染动物模型的构建方法及其用途
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025133105A1 (en) * 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025140421A1 (zh) * 2023-12-29 2025-07-03 北京剂泰医药科技有限公司 可电离脂质化合物及其在递送核酸疫苗中的用途
WO2025166323A2 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. Crispr-related methods and compositions targeting lipoprotein (a) expression
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202543583A (zh) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 用於將治療劑包覆於脂質奈米顆粒中之材料及方法
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
TW202602839A (zh) 2024-04-10 2026-01-16 加拿大商阿奎特斯醫療公司 用於脂質奈米顆粒之陽離子脂質化合物
CN118319880B (zh) * 2024-04-15 2025-02-07 荣灿生物医药技术(上海)有限公司 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026035680A1 (en) 2024-08-06 2026-02-12 Kernal Biologics, Inc. Compositions and methods for delivery of agents
CN119431176B (zh) * 2024-11-05 2026-02-13 汉信生物科技(苏州)有限公司 一种可电离阳离子脂质及其制备方法和应用

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360257A2 (en) 1988-09-20 1990-03-28 The Board Of Regents For Northern Illinois University RNA catalyst for cleaving specific RNA sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1991003162A1 (en) 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
WO1993015187A1 (en) 1992-01-31 1993-08-05 Massachusetts Institute Of Technology Nucleozymes
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
WO1994013688A1 (en) 1992-12-08 1994-06-23 Gene Shears Pty. Limited Dna-armed ribozymes and minizymes
US5334711A (en) 1991-06-20 1994-08-02 Europaisches Laboratorium Fur Molekularbiologie (Embl) Synthetic catalytic oligonucleotide structures
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5610288A (en) 1993-01-27 1997-03-11 Hekton Institute For Medical Research Antisense polynucleotide inhibition of epidermal human growth factor receptor expression
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5718709A (en) 1988-09-24 1998-02-17 Considine; John Apparatus for removing tumours from hollow organs of the body
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5759829A (en) 1986-03-28 1998-06-02 Calgene, Inc. Antisense regulation of gene expression in plant cells
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
WO2001007548A1 (en) 1999-07-26 2001-02-01 The Procter & Gamble Company Cationic charge boosting systems
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
US20040142025A1 (en) 2002-06-28 2004-07-22 Protiva Biotherapeutics Ltd. Liposomal apparatus and manufacturing methods
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
US20040262223A1 (en) 2001-07-27 2004-12-30 President And Fellows Of Harvard College Laminar mixing apparatus and methods
US20050017054A1 (en) 2003-07-23 2005-01-27 Tom Iverson Flyback transformer wire attach method to printed circuit board
US20050064595A1 (en) 2003-07-16 2005-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US20050118253A1 (en) 1998-02-03 2005-06-02 Protiva Biotherapeutics, Inc. Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20060008910A1 (en) 2004-06-07 2006-01-12 Protiva Biotherapeuties, Inc. Lipid encapsulated interfering RNA
US20060083780A1 (en) 2004-06-07 2006-04-20 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US20070042031A1 (en) 2005-07-27 2007-02-22 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20070123482A1 (en) 2005-08-10 2007-05-31 Markus Stoffel Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2008036825A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2010054401A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20100130588A1 (en) 2008-04-15 2010-05-27 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010144740A1 (en) 2009-06-10 2010-12-16 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
WO2011127255A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012013326A1 (en) 2010-07-30 2012-02-02 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012024526A2 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20120172411A1 (en) 2010-09-17 2012-07-05 Protiva Biotherapeutics, Inc. Novel trialkyl cationic lipids and methods of use thereof
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US20120251618A1 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US20120276209A1 (en) 2009-11-04 2012-11-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US20120295832A1 (en) 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20130086373A1 (en) 2011-09-29 2013-04-04 Apple Inc. Customized content for electronic devices
US20130150625A1 (en) 2010-05-24 2013-06-13 Brian W. Budzik Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130164400A1 (en) 2011-11-04 2013-06-27 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130245107A1 (en) 2011-12-16 2013-09-19 modeRNA Therapeutics Dlin-mc3-dma lipid nanoparticle delivery of modified polynucleotides
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
WO2015199952A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061426A2 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
DE69810781T2 (de) 1997-08-15 2003-09-25 Chisso Corp., Osaka Polydisperses propylenpolymer und verfahren zu dessen herstellung
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2015011633A1 (en) * 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
BR112019008481A2 (pt) * 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
ES3063077T3 (en) * 2016-10-26 2026-04-15 Acuitas Therapeutics Inc Lipid nanoparticle formulations
EP3551169A4 (en) * 2016-12-09 2020-09-09 Sangamo Therapeutics, Inc. TARGET-SPECIFIC NUCLEASES ADMINISTRATION
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
PT3688162T (pt) 2017-09-29 2024-04-23 Intellia Therapeutics Inc Formulações
WO2019089828A1 (en) * 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
CA3080592A1 (en) 2017-10-31 2019-05-09 Modernatx, Inc. Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
MY202837A (en) 2019-01-11 2024-05-24 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759829A (en) 1986-03-28 1998-06-02 Calgene, Inc. Antisense regulation of gene expression in plant cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0360257A2 (en) 1988-09-20 1990-03-28 The Board Of Regents For Northern Illinois University RNA catalyst for cleaving specific RNA sequences
US5718709A (en) 1988-09-24 1998-02-17 Considine; John Apparatus for removing tumours from hollow organs of the body
WO1991003162A1 (en) 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5334711A (en) 1991-06-20 1994-08-02 Europaisches Laboratorium Fur Molekularbiologie (Embl) Synthetic catalytic oligonucleotide structures
WO1993015187A1 (en) 1992-01-31 1993-08-05 Massachusetts Institute Of Technology Nucleozymes
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
WO1994013688A1 (en) 1992-12-08 1994-06-23 Gene Shears Pty. Limited Dna-armed ribozymes and minizymes
US5610288A (en) 1993-01-27 1997-03-11 Hekton Institute For Medical Research Antisense polynucleotide inhibition of epidermal human growth factor receptor expression
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US20050118253A1 (en) 1998-02-03 2005-06-02 Protiva Biotherapeutics, Inc. Systemic delivery of serum stable plasmid lipid particles for cancer therapy
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
WO2001007548A1 (en) 1999-07-26 2001-02-01 The Procter & Gamble Company Cationic charge boosting systems
US20040262223A1 (en) 2001-07-27 2004-12-30 President And Fellows Of Harvard College Laminar mixing apparatus and methods
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20040142025A1 (en) 2002-06-28 2004-07-22 Protiva Biotherapeutics Ltd. Liposomal apparatus and manufacturing methods
US20110216622A1 (en) 2002-06-28 2011-09-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing method
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
US20050064595A1 (en) 2003-07-16 2005-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US20060240093A1 (en) 2003-07-16 2006-10-26 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20120058188A1 (en) 2003-07-16 2012-03-08 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20050017054A1 (en) 2003-07-23 2005-01-27 Tom Iverson Flyback transformer wire attach method to printed circuit board
US20110091525A1 (en) 2003-09-15 2011-04-21 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20110262527A1 (en) 2004-06-07 2011-10-27 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US20060008910A1 (en) 2004-06-07 2006-01-12 Protiva Biotherapeuties, Inc. Lipid encapsulated interfering RNA
US20060083780A1 (en) 2004-06-07 2006-04-20 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US20110060032A1 (en) 2004-06-07 2011-03-10 Protiva Biotherapeutics, Inc. Lipid encapsulating interfering rna
US20070042031A1 (en) 2005-07-27 2007-02-22 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070123482A1 (en) 2005-08-10 2007-05-31 Markus Stoffel Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
WO2008036825A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
US20100130588A1 (en) 2008-04-15 2010-05-27 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US20120183581A1 (en) 2008-04-15 2012-07-19 Protiva Biotherapeutics, Inc Novel lipid formulations for nucleic acid delivery
US8492359B2 (en) 2008-04-15 2013-07-23 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2010054401A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20160199485A1 (en) 2008-11-10 2016-07-14 Tekmira Pharmaceuticals Corporation Novel lipids and compositions for the delivery of therapeutics
US20110311582A1 (en) 2008-11-10 2011-12-22 Muthiah Manoharan Novel lipids and compositions for the delivery of therapeutics
US20110311583A1 (en) 2008-11-10 2011-12-22 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20150265708A1 (en) 2008-11-10 2015-09-24 Tekmira Pharmaceuticals Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010144740A1 (en) 2009-06-10 2010-12-16 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20120276209A1 (en) 2009-11-04 2012-11-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011127255A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US20130150625A1 (en) 2010-05-24 2013-06-13 Brian W. Budzik Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery
US20160009637A1 (en) 2010-06-03 2016-01-14 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012013326A1 (en) 2010-07-30 2012-02-02 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US20130142818A1 (en) 2010-07-30 2013-06-06 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012024526A2 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20120172411A1 (en) 2010-09-17 2012-07-05 Protiva Biotherapeutics, Inc. Novel trialkyl cationic lipids and methods of use thereof
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US20140200257A1 (en) 2011-01-11 2014-07-17 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US20120251618A1 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US20120295832A1 (en) 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
US20130086373A1 (en) 2011-09-29 2013-04-04 Apple Inc. Customized content for electronic devices
WO2013093648A2 (en) 2011-11-04 2013-06-27 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US20130164400A1 (en) 2011-11-04 2013-06-27 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20150005363A1 (en) 2011-12-07 2015-01-01 Alnylam Pharmaceuticals, Inc. Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20150273068A1 (en) 2011-12-07 2015-10-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20130245107A1 (en) 2011-12-16 2013-09-19 modeRNA Therapeutics Dlin-mc3-dma lipid nanoparticle delivery of modified polynucleotides
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
US20150376115A1 (en) 2014-06-25 2015-12-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2015199952A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017004143A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061426A2 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes

Also Published As

Publication number Publication date
GB2600859B (en) 2024-04-03
EP4454640A2 (en) 2024-10-30
IL290477A (en) 2022-04-01
DOP2022000038A (es) 2023-01-31
WO2021030701A1 (en) 2021-02-18
PL4013385T3 (pl) 2024-11-18
EP4454640A3 (en) 2025-02-12
BR112022002708A2 (pt) 2022-05-31
SI4013385T1 (sl) 2024-10-30
MX2025003983A (es) 2025-05-02
EP4013385A1 (en) 2022-06-22
CN114901253A (zh) 2022-08-12
CA3150458A1 (en) 2021-02-18
CL2022000351A1 (es) 2023-02-03
MX2022001720A (es) 2022-03-11
AU2020328596B2 (en) 2026-02-12
ECSP22018209A (es) 2022-07-29
JP2025173509A (ja) 2025-11-27
CR20220108A (es) 2022-05-27
LT4013385T (lt) 2024-09-25
PH12022550363A1 (en) 2023-02-27
ES2992930T3 (en) 2024-12-19
JP7753190B2 (ja) 2025-10-14
AU2020328596A1 (en) 2022-03-31
ES2918001A2 (es) 2022-07-13
EP4013385B1 (en) 2024-07-03
JOP20220037A1 (ar) 2023-01-30
GB2600859A (en) 2022-05-11
DK4013385T3 (da) 2024-09-02
GEAP202515904A (en) 2025-07-10
HUE068356T2 (hu) 2024-12-28
KR20220053599A (ko) 2022-04-29
ES2918001R1 (es) 2025-02-18
GEP20257820B (en) 2025-11-10
CO2022002685A2 (es) 2022-04-19
HRP20241255T1 (hr) 2024-12-06
US20230097090A1 (en) 2023-03-30
PE20220968A1 (es) 2022-06-10
FI4013385T3 (fi) 2024-09-27
UA129330C2 (uk) 2025-03-19
PT4013385T (pt) 2024-10-01
JP2022544652A (ja) 2022-10-20

Similar Documents

Publication Publication Date Title
EP4013385B1 (en) Improved lipid nanoparticles for delivery of nucleic acids
JP7086870B2 (ja) メッセンジャーｒｎａを送達するための組成物及び方法
JP5766188B2 (ja) 固形腫瘍に治療剤を送達するための脂質製剤
CN107208095B (zh) 用于使乙型肝炎病毒基因表达沉默的组合物和方法
US9222086B2 (en) Compositions and methods for silencing genes expressed in cancer
EP2281041B1 (en) Silencing of csn5 gene expression using interfering rna
JP2022009505A (ja) メッセンジャーｒｎａを送達するための組成物及び方法
EP4714454A2 (en) Lipid nanoparticle formulations
US20250248939A1 (en) Lipid nanoparticles, nucleic acids, and methods of use
JP2011521649A (ja) 遺伝子発現を改変するための標的化オリゴヌクレオチド組成物
CN115956072A (zh) 一类阳离子脂质化合物及其应用
CN117582510B (zh) 金属-多酚复合物在核酸递送系统中的应用
HK40117910A (en) Improved lipid nanoparticles for delivery of nucleic acids
HK40076667A (en) Improved lipid nanoparticles for delivery of nucleic acids
HK40076667B (en) Improved lipid nanoparticles for delivery of nucleic acids
DE102010056610A1 (de) Pharmazeutische Zusammensetzung enthaltend L-DNA
WO2026083241A1 (en) Ionizable lipids comprising n,n-substituted hydroxylamine esters
CN117582511A (zh) 金属-磷脂复合物颗粒及其制备方法与应用
TR2022001658T2 (tr) Nükleik asitlerin uygulanması için geliştirilmiş lipid nano-tanecikleri.

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication